Continuous Digitalized Processes for Producing Biopharmaceuticals
Developing a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine.
Projectdetails
Introduction
Biopharmaceuticals are essential for the medical treatment of diseases like immune deficiencies, cancer, and diabetes, and provide an indispensable component to the health care system worldwide, as showcased by mRNA vaccines in the recent pandemic. Despite this success, manufacturing is still based on traditional, outdated batch production technologies, and on process development procedures based on historical experience and empiricism leading to many inefficiencies, like very long values of time-to-market.
Need for Modernization
There is an urgent need to introduce modern integrated, continuous, and fully digitalized production processes to also cope with the upcoming cell and gene therapies and the emerging personalized medicine. I develop here revolutionary process development and operation methodologies to enable this.
Digital Twin Approach
These methodologies are based on a Digital Twin, which includes the first continuous, integrated, and fully digitalized plant for producing mRNA. The “engine” consists of innovative hybrid models for each unit of the plant, which are updated in real time through continuous learning techniques. These provide the predictive capabilities needed for:
- Monitoring and control
- Knowledge transfer
- Scenario analysis
- Experimental planning
Development of Hybrid Models
I will develop a new generation of hybrid models and innovative machine learning algorithms and provide the experimental evaluation and validation of my methodologies. Other high precision continuous processes, like flow-chemistry for sustainable catalytic processes or microfluidics for the controlled synthesis of nanomaterials, will benefit from these results.
Expertise and Impact
I am a recognized pioneer in the scientific foundations of continuous operation in biopharma. This inspired me to develop this disruptive Digital-Twin-based methodology and cope with the associated high risk. With about 110 PhD students advised in my career and now active in Academia and Industry, I know how to inspire a new generation of scientists with the novel science emerging from this project.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 2.500.000 |
Tijdlijn
Startdatum | 1-10-2023 |
Einddatum | 30-9-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ARISTOTELIO PANEPISTIMIO THESSALONIKISpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industryBURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals. | ERC Proof of... | € 150.000 | 2024 | Details |
Decellularised Extracellular Carpets for the Innovative Production of Human Engineered ReplicatesThis project aims to accelerate the development of cell-derived products using macromolecular crowding, enhancing European biotech competitiveness and creating new jobs and markets. | ERC Proof of... | € 150.000 | 2024 | Details |
Plant based 4D biohybrid systemsThe 4D-PhytoHybrid project aims to create advanced photosynthetic biohybrid systems that integrate living plant cells with electronic materials to develop innovative hybrid technologies. | ERC Starting... | € 1.499.477 | 2022 | Details |
Integrated Mechanistic Modelling and Analysis of Large-scale Biomedical DataINTEGRATE aims to enhance cancer treatment by developing advanced computational models that integrate patient-derived data for improved drug targeting and clinical trial planning. | ERC Consolid... | € 1.854.546 | 2024 | Details |
Learning and modeling the molecular response of single cells to drug perturbationsDeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings. | ERC Advanced... | € 2.497.298 | 2023 | Details |
Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry
BURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals.
Decellularised Extracellular Carpets for the Innovative Production of Human Engineered Replicates
This project aims to accelerate the development of cell-derived products using macromolecular crowding, enhancing European biotech competitiveness and creating new jobs and markets.
Plant based 4D biohybrid systems
The 4D-PhytoHybrid project aims to create advanced photosynthetic biohybrid systems that integrate living plant cells with electronic materials to develop innovative hybrid technologies.
Integrated Mechanistic Modelling and Analysis of Large-scale Biomedical Data
INTEGRATE aims to enhance cancer treatment by developing advanced computational models that integrate patient-derived data for improved drug targeting and clinical trial planning.
Learning and modeling the molecular response of single cells to drug perturbations
DeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturingThe project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing. | EIC Pathfinder | € 3.617.783 | 2022 | Details |
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process controlThe SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors. | EIC Pathfinder | € 1.364.281 | 2022 | Details |
Yeast cell factory for mRNA bioproductionYscript aims to revolutionize mRNA production by using yeast for efficient, cost-effective bioproduction and purification, enhancing therapeutic quality and accessibility in healthcare. | EIC Pathfinder | € 3.078.249 | 2022 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Biopharmaceuticals purification by continuous membrane-assisted crystallization achieving lower cost and intensified processesThe BIOPURE project aims to revolutionize monoclonal antibody purification using innovative membrane technology to enhance efficiency, reduce costs, and improve access to biomedicines. | EIC Transition | € 2.069.150 | 2023 | Details |
Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing
The project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing.
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.
Yeast cell factory for mRNA bioproduction
Yscript aims to revolutionize mRNA production by using yeast for efficient, cost-effective bioproduction and purification, enhancing therapeutic quality and accessibility in healthcare.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
Biopharmaceuticals purification by continuous membrane-assisted crystallization achieving lower cost and intensified processes
The BIOPURE project aims to revolutionize monoclonal antibody purification using innovative membrane technology to enhance efficiency, reduce costs, and improve access to biomedicines.